Home/Pipeline/APJ Program

APJ Program

Obesity

PreclinicalActive

Key Facts

Indication

Obesity

Phase

Preclinical

Status

Active

Company

BioAge Labs

About BioAge Labs

BioAge Labs harnesses aging biology to develop novel therapies for obesity and metabolic diseases through their proprietary multi-omics discovery platform. Their lead candidate BGE-102 targets NLRP3-mediated inflammation, while their APJ program aims to mimic exercise benefits for obesity treatment. The company recently completed a $115 million public offering and trades on NASDAQ under ticker BIOA.

View full company profile

Therapeutic Areas

Metabolic Diseases Obesity Cardiovascular Disease Diabetes Complications Aging Biology

Other Obesity Drugs

Drug	Company	Phase	Status
Tirzepatide (Zepbound)	Eli Lilly	Approved	Commercial
Wegovy HD (semaglutide 7.2mg)	Novo Nordisk	Approved	Recently approved in US
Amylin analogue (subcutaneous)	Novo Nordisk	Phase 1	Active
GLP1-GIP-Amylin tri-agonist	Novo Nordisk	Phase 2	Active
VK2735 (subcutaneous)	Viking Therapeutics	Phase 3	Active
VK2735 (oral)	Viking Therapeutics	Phase 1/2	Active
GSBR-1290	Structure Therapeutics	Phase 2	Active, not recruiting
LTSE-2578	Structure Therapeutics	Preclinical	Lead Optimization
Survodutide (BI 456906)	Zealand Pharma	Phase 3	Active
ZP8396	Zealand Pharma	Preclinical/Phase 1	Active
Pemvidutide (ALT-801)	Altimmune	Phase 2	Active
PL7737	Palatin Technologies	Preclinical	Active